Literature DB >> 10223754

Colorectal cancer in inflammatory bowel disease: a continuing problem.

R Mayer1, W D Wong, D A Rothenberger, S M Goldberg, R D Madoff.   

Abstract

PURPOSE: Because of the increased risk of colorectal cancer in patients with inflammatory bowel disease, surveillance colonoscopy with mucosal biopsies for dysplasia has been advocated to prevent malignancy or permit its early diagnosis. However, despite adoption of colonoscopic surveillance programs by many clinicians, we have noted a pattern of continued referrals for inflammatory bowel disease-associated malignancy. This study was undertaken in an effort to characterize this cohort of patients.
METHODS: We reviewed the operative records of a large metropolitan colorectal practice from 1983 to 1995. During this period 40 large-bowel resections were performed for patients with documented inflammatory bowel disease and concomitant carcinoma. A retrospective analysis was conducted with emphasis on clinical presentation, pathologic description, and most recent follow-up.
RESULTS: Mean age at the time of diagnosis of cancer was 48 years with an average inflammatory bowel disease duration of 19 years. Seven patients had documented inflammatory bowel disease for less than eight years before their cancer diagnosis. Carcinomas were identified preoperatively by colonoscopy in 92 percent of patients. One-half of these patients had the colonoscopy to investigate a recent change in inflammatory bowel disease symptoms or signs, whereas the other half underwent endoscopy as routine surveillance. For the remaining 8 percent of patients, operated on for worsening symptoms, the carcinoma was detected in the pathological specimen only. The majority of patients (68 percent) did not have a preoperative diagnosis of dysplasia. Twenty-five percent of tumors were mucinous, 20 percent were multicentric, and 70 percent were located distal to the splenic flexure. Among the seven patients who died, four had pancolitis, six had a recent worsening of symptoms, and all had cancer involving the rectum.
CONCLUSION: Cancer occurs at a younger age in patients with long-standing inflammatory bowel disease. The tumors are often mucinous, multiple, and located in the left colon. Despite increasing acceptance of surveillance colonoscopy as a recommended strategy in cancer prevention, almost one-half of the patients in this study had their cancer diagnosed because increased colitis symptoms led to colonoscopic examination. Eighteen percent of patients developed cancer with less than an eight-year history of inflammatory bowel disease. These data call into question the effectiveness of dysplasia surveillance as a population-based strategy to decrease the colorectal cancer mortality in inflammatory bowel disease patients.

Entities:  

Mesh:

Year:  1999        PMID: 10223754     DOI: 10.1007/bf02236351

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  12 in total

Review 1.  Cancer surveillance in inflammatory bowel disease.

Authors:  C N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  1999-12

2.  Colitic cancer developed after introduction of azathioprine.

Authors:  Jun-ichi Sasaki; Yutaka J Kawamura; Fumio Konishi; Tsutomu Tosha
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

Review 3.  Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies.

Authors:  Peter-Laszlo Lakatos; Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

4.  Tumor recognition of peanut agglutinin-immobilized fluorescent nanospheres in biopsied human tissues.

Authors:  Hironori Kumagai; Kosuke Yamada; Kanako Nakai; Tokio Kitamura; Kohta Mohri; Masami Ukawa; Takumi Tomono; Takaaki Eguchi; Testuya Yoshizaki; Takumi Fukuchi; Takuya Yoshino; Minoru Matsuura; Etsuo Tobita; Wellington Pham; Hiroshi Nakase; Shinji Sakuma
Journal:  Eur J Pharm Biopharm       Date:  2019-01-09       Impact factor: 5.571

5.  p27 expression in inflammatory bowel disease-associated neoplasia. Further evidence of a unique molecular pathogenesis.

Authors:  S Walsh; M Murphy; M Silverman; R Odze; D Antonioli; H Goldman; M Loda
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

6.  Detection of intestinal cancer by local, topical application of a quenched fluorescence probe for cysteine cathepsins.

Authors:  Ehud Segal; Tyler R Prestwood; Wouter A van der Linden; Yaron Carmi; Nupur Bhattacharya; Nimali Withana; Martijn Verdoes; Aida Habtezion; Edgar G Engleman; Matthew Bogyo
Journal:  Chem Biol       Date:  2015-01-08

7.  Tumor suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated carcinoma.

Authors:  Caitlyn W Barrett; Wei Ning; Xi Chen; Jesse Joshua Smith; Mary K Washington; Kristina E Hill; Lori A Coburn; Richard M Peek; Rupesh Chaturvedi; Keith T Wilson; Raymond F Burk; Christopher S Williams
Journal:  Cancer Res       Date:  2012-12-05       Impact factor: 12.701

Review 8.  Colorectal cancer in inflammatory bowel disease: review of the evidence.

Authors:  D S Keller; A Windsor; R Cohen; M Chand
Journal:  Tech Coloproctol       Date:  2019-01-30       Impact factor: 3.781

9.  Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy.

Authors:  Pei-Lin Hsiung; Pei-Lei Hsiung; Jonathan Hardy; Shai Friedland; Roy Soetikno; Christine B Du; Amy P Wu; Peyman Sahbaie; James M Crawford; Anson W Lowe; Christopher H Contag; Thomas D Wang
Journal:  Nat Med       Date:  2008-03-16       Impact factor: 53.440

10.  Specificity of lectin-immobilized fluorescent nanospheres for colorectal tumors in a mouse model which better resembles the clinical disease.

Authors:  Tokio Kitamura; Shinji Sakuma; Moe Shimosato; Haruki Higashino; Yoshie Masaoka; Makoto Kataoka; Shinji Yamashita; Ken-Ichiro Hiwatari; Hironori Kumagai; Naoki Morimoto; Seiji Koike; Etsuo Tobita; Robert M Hoffman; John C Gore; Wellington Pham
Journal:  Contrast Media Mol Imaging       Date:  2014-06-27       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.